Abstract:Heat shock protein 90 (HSP90) is overexpressed in numerous cancers, promotes the maturation of numerous oncoproteins and facilitates cancer cell growth. Certain HSP90 inhibitors have entered clinical trials. Although less than satisfactory clinical effects or insurmountable toxicity have compelled these trials to be terminated or postponed, these results of preclinical and clinical studies demonstrated that the prospects of targeting therapeutic strategies involving HSP90 inhibitors deserve enough attention. Nanoparticulate-based drug delivery systems have been generally supposed as one of the most promising formulations especially for targeting strategies. However, so far, no active targeting nano-formulations have succeeded in clinical translation, mainly due to complicated preparation, complex formulations leading to difficult industrialization, incomplete biocompatibility or nontoxicity. In this study, HSP90 and CD44-targeted A6 peptide functionalized biomimetic nanoparticles (A6-NP) was designed and various degrees of A6-modification on nanoparticles were fabricated to evaluate targeting ability and anticancer efficiency. With no excipients, the hydrophobic HSP90 inhibitor G2111 and A6-conjugated human serum albumin could self-assemble into nanoparticles with a uniform particle size of approximately 200 nm, easy fabrication, well biocompatibility and avoidance of hepatotoxicity. Besides, G2111 encapsulated in A6-NP was only released less than 5% in 12 h, which may avoid off-target cell toxicity before entering into cancer cells. A6 peptide modification could significantly enhance uptake within a short time. Moreover, A6-NP continues to exert the broad anticancer spectrum of Hsp90 inhibitors and displays remarkable targeting ability and anticancer efficacy both in hematological malignancies and solid tumors (with colon tumors as the model cancer) both in vitro and in vivo. Overall, A6-NP, as a simple, biomimetic and active dual-targeting (CD44 and HSP90) nanomedicine, displays high potential for clinical translation.

A6 Peptide-Tagged, Ultra-Small and Reduction-Sensitive Polymersomal Vincristine Sulfate As a Smart and Specific Treatment for CD44+ Acute Myeloid Leukemia.

Nano-drug Delivery System for the Treatment of Acute Myelogenous Leukemia.

A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells

A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia

Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia

CD44‐Specific A6 Short Peptide Boosts Targetability and Anticancer Efficacy of Polymersomal Epirubicin to Orthotopic Human Multiple Myeloma

Synthetic CXCR4 Antagonistic Peptide Assembling with Nanoscaled Micelles Combat Acute Myeloid Leukemia.

CD123 Antagonistic Peptides Assembled with Nanomicelles Act As Monotherapeutics to Combat Refractory Acute Myeloid Leukemia

A small molecule BCL6 inhibitor as chemosensitizers in acute myeloid leukemia

Engineering and Characterization of Hu3A4: A Novel Humanized Antibody with Potential As a Therapeutic Agent Against Myeloid Lineage Leukemias

Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical PLK1 inhibitor to acute myeloid leukemia

Exogenous Antigen Upregulation Empowers Antibody Targeted Nanochemotherapy of Leukaemia

Smart and Generalizable Cytarabine Derivative-Triggered Nanoparticles for Synergistic Therapy of Relapsed/Refractory Acute Myeloid Leukemia

Nanomicelles co-loading CXCR4 antagonist and doxorubicin combat the refractory acute myeloid leukemia

CXCR4 and CD44 Dual-Targeted Prussian Blue Nanosystem with Daunorubicin Loaded for Acute Myeloid Leukemia Therapy

Use of Polymeric CXCR4 Inhibitors As Sirna Delivery Vehicles for the Treatment of Acute Myeloid Leukemia

A Novel Small Molecule CXCR4 Antagonist Improves Anticancer Therapy by Blocking the Interaction of Malignant Cells with Their Associated Niches

Targeted delivery of HSP90 inhibitors for efficient therapy of CD44-positive acute myeloid leukemia and solid tumor-colon cancer

An Ultra-Long Circulating Nanoparticle for Reviving a Highly Selective BCR-ABL Inhibitor in Long-Term Effective and Safe Treatment of Chronic Myeloid Leukemia

Vincristine loaded pegylated liposomal drug delivery for efficient treatment of acute lymphoblastic leukaemia

Structure-based identification of new orally bioavailable BRD9-PROTACs for treating acute myelocytic leukemia